Thompson H J, Adlakha H
Laboratory of Nutrition Research, AMC Cancer Research Center, Denver, Colorado 80214.
Cancer Res. 1991 Jul 1;51(13):3411-5.
Dose-response relationships for the induction of mammary tumors by a single i.p. injection of 1-methyl-1-nitrosourea (MNU) were studied. Groups of 30 female Sprague-Dawley rats were given i.p. injections of 50, 37.5, 25, 12.5, or 0 mg MNU/kg body weight at 50 days of age. Animals were palpated for tumor detection twice weekly throughout a 28-week observation period. Administration of MNU i.p. caused no acute toxicity. Both benign and malignant mammary tumors were induced by MNU, but malignant tumors appeared earlier and at a faster rate than benign tumors. The incidence and numbers of mammary carcinomas increased whereas median cancer-free time decreased with increasing dose of MNU. Approximately twice as many mammary cancers were observed in the cervical-thoracic as in the abdominal-inguinal mammary gland chains irrespective of carcinogen dose, while the frequency of tumor occurrence in the left versus right chains was similar. Tumor latency decreased with increasing dose of MNU, but the quartiles for time to detection of all tumors within each carcinogen dose group were similar irrespective of anatomical region in which the tumors occurred. The mammary tumor response attained via i.p. injection was similar but the coefficient of variation for tumor multiplicity within a carcinogen dose group was lower in comparison to that observed when MNU was administered i.v. or s.c. Among these techniques for carcinogen injection, the i.p. route is the most rapid method and offers an added advantage of ease of administration with quantitative, reproducible delivery of the desired amount of carcinogen and a decrease in variability of tumor response among animals within a treatment group. This method is well suited for the technically less experienced investigator and for those in need for a rapid method of injecting MNU to large numbers of animals.
研究了单次腹腔注射1-甲基-1-亚硝基脲(MNU)诱导乳腺肿瘤的剂量反应关系。将30只雌性斯普拉格-道利大鼠分为几组,在50日龄时腹腔注射50、37.5、25、12.5或0 mg MNU/kg体重。在整个28周的观察期内,每周两次对动物进行触诊以检测肿瘤。腹腔注射MNU未引起急性毒性。MNU可诱导良性和恶性乳腺肿瘤,但恶性肿瘤出现得更早,且比良性肿瘤生长速度更快。随着MNU剂量的增加,乳腺癌的发病率和数量增加,而无癌中位时间缩短。无论致癌物剂量如何,在颈胸段乳腺链中观察到的乳腺癌数量约为腹腹股沟乳腺链中的两倍,而左右乳腺链中肿瘤发生的频率相似。肿瘤潜伏期随MNU剂量的增加而缩短,但每个致癌物剂量组内所有肿瘤检测时间的四分位数相似,与肿瘤发生的解剖区域无关。通过腹腔注射获得的乳腺肿瘤反应相似,但与静脉注射或皮下注射MNU时相比,致癌物剂量组内肿瘤多样性的变异系数更低。在这些致癌物注射技术中,腹腔注射途径是最快速的方法,并且具有易于给药的额外优势,能够定量、可重复地递送所需量的致癌物,并降低治疗组内动物间肿瘤反应的变异性。该方法非常适合技术经验较少的研究人员以及那些需要快速向大量动物注射MNU的人员。